^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Source:
Title:

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

Excerpt:
An acquired resistance mechanism activating the MAPK pathway was identified in 9 of 11 Prog tumours (82%; Table 1; Fig. 1); BRAF amplifications were detected in 4 (36%), MEK1/2 mutations in 3 (27%) and oncogenic NRAS mutations in 3 (27%) Prog tumours (Figs 1 and 2).
DOI:
10.1038/ncomms6694
Trial ID: